Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
4.300
-0.160 (-3.59%)
At close: Mar 31, 2025, 4:00 PM
4.454
+0.154 (3.59%)
After-hours: Mar 31, 2025, 7:29 PM EDT
Jasper Therapeutics Employees
Jasper Therapeutics had 64 employees as of December 31, 2024. The number of employees increased by 19 or 42.22% compared to the previous year.
Employees
64
Change (1Y)
19
Growth (1Y)
42.22%
Revenue / Employee
n/a
Profits / Employee
-$1,113,578
Market Cap
64.60M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64 | 19 | 42.22% |
Dec 31, 2023 | 45 | 10 | 28.57% |
Dec 31, 2022 | 35 | 10 | 40.00% |
Dec 31, 2021 | 25 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
JSPR News
- 4 weeks ago - Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting - GlobeNewsWire
- 4 weeks ago - Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting - GlobeNewsWire
- 4 weeks ago - Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Jasper Therapeutics to Present at Upcoming March Investor Conferences - GlobeNewsWire
- 7 weeks ago - Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting - GlobeNewsWire
- 7 weeks ago - Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria - GlobeNewsWire
- 3 months ago - Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025 - GlobeNewsWire